Thermo Fisher Scientific Inc. (NYSE: TMO) Stock Competitors & Peer Comparison
See TMO's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TMO and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TMO | $675.00 | -0.50% | 249.1B | 29.09 | $23.16 | +0.27% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.64% |
| DHR | $224.49 | +0.32% | 157.8B | 28.14 | $7.98 | +0.64% |
| NTRA | $412.56 | +0.92% | 59.1B | -312.55 | -$1.32 | N/A |
| A | $172.79 | -0.03% | 48.8B | 29.74 | $5.81 | +0.59% |
| IQV | $270.37 | -1.69% | 44.4B | 22.24 | $12.13 | N/A |
| WAT | $433.54 | +0.75% | 42.6B | 31.71 | $13.68 | N/A |
| IDXX | $519.26 | +1.14% | 41B | 36.52 | $14.22 | N/A |
| ILMN | $270.00 | -1.42% | 40.9B | 53.68 | $5.03 | N/A |
| MTD | $1,511.64 | -0.49% | 30.5B | 34.73 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
TMO vs DHR-PB Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, TMO's ROE is +0.13%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, TMO is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for TMO.Check DHR-PB's competition here
Danaher Corporation (NYSE: DHR)
TMO vs DHR Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, DHR has a market cap of 157.8B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while DHR trades at $224.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas DHR's P/E ratio is 28.14. In terms of profitability, TMO's ROE is +0.13%, compared to DHR's ROE of +0.08%. Regarding short-term risk, TMO is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for TMO.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
TMO vs NTRA Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, NTRA has a market cap of 59.1B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while NTRA trades at $412.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas NTRA's P/E ratio is -312.55. In terms of profitability, TMO's ROE is +0.13%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, TMO is similarly volatile compared to NTRA. This indicates similar risk in terms of short-term price fluctuations for TMO.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
TMO vs A Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, A has a market cap of 48.8B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while A trades at $172.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas A's P/E ratio is 29.74. In terms of profitability, TMO's ROE is +0.13%, compared to A's ROE of +0.20%. Regarding short-term risk, TMO is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for TMO.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
TMO vs IQV Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, IQV has a market cap of 44.4B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while IQV trades at $270.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas IQV's P/E ratio is 22.24. In terms of profitability, TMO's ROE is +0.13%, compared to IQV's ROE of +0.22%. Regarding short-term risk, TMO is similarly volatile compared to IQV. This indicates similar risk in terms of short-term price fluctuations for TMO.Check IQV's competition here
Waters Corporation (NYSE: WAT)
TMO vs WAT Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, WAT has a market cap of 42.6B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while WAT trades at $433.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas WAT's P/E ratio is 31.71. In terms of profitability, TMO's ROE is +0.13%, compared to WAT's ROE of +0.02%. Regarding short-term risk, TMO is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for TMO.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
TMO vs IDXX Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, IDXX has a market cap of 41B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while IDXX trades at $519.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas IDXX's P/E ratio is 36.52. In terms of profitability, TMO's ROE is +0.13%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, TMO is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for TMO.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
TMO vs ILMN Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, ILMN has a market cap of 40.9B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while ILMN trades at $270.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas ILMN's P/E ratio is 53.68. In terms of profitability, TMO's ROE is +0.13%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, TMO is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
TMO vs MTD Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, MTD has a market cap of 30.5B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while MTD trades at $1,511.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas MTD's P/E ratio is 34.73. In terms of profitability, TMO's ROE is +0.13%, compared to MTD's ROE of -12.00%. Regarding short-term risk, TMO is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for TMO.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
TMO vs DGX Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, DGX has a market cap of 26.1B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while DGX trades at $236.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas DGX's P/E ratio is 23.30. In terms of profitability, TMO's ROE is +0.13%, compared to DGX's ROE of +0.14%. Regarding short-term risk, TMO is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for TMO.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
TMO vs LH Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while LH trades at $309.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas LH's P/E ratio is 18.37. In terms of profitability, TMO's ROE is +0.13%, compared to LH's ROE of +0.12%. Regarding short-term risk, TMO is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for TMO.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
TMO vs GH Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, GH has a market cap of 23.7B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while GH trades at $177.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas GH's P/E ratio is -50.56. In terms of profitability, TMO's ROE is +0.13%, compared to GH's ROE of +2.11%. Regarding short-term risk, TMO is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for TMO.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
TMO vs EXAS Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas EXAS's P/E ratio is -95.37. In terms of profitability, TMO's ROE is +0.13%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, TMO is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for TMO.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
TMO vs MEDP Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while MEDP trades at $618.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas MEDP's P/E ratio is 36.28. In terms of profitability, TMO's ROE is +0.13%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, TMO is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
TMO vs ILMNV Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas ILMNV's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to ILMNV's ROE of N/A. Regarding short-term risk, TMO is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for TMO.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
TMO vs RVTY Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, RVTY has a market cap of 16.9B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while RVTY trades at $151.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas RVTY's P/E ratio is 28.24. In terms of profitability, TMO's ROE is +0.13%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, TMO is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for TMO.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
TMO vs PKI Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas PKI's P/E ratio is 41.45. In terms of profitability, TMO's ROE is +0.13%, compared to PKI's ROE of +0.03%. Regarding short-term risk, TMO is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for TMO.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
TMO vs CRL Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, CRL has a market cap of 14.1B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while CRL trades at $292.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas CRL's P/E ratio is 29.61. In terms of profitability, TMO's ROE is +0.13%, compared to CRL's ROE of -0.08%. Regarding short-term risk, TMO is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
TMO vs ICLR Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while ICLR trades at $172.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas ICLR's P/E ratio is 14.06. In terms of profitability, TMO's ROE is +0.13%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, TMO is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
TMO vs QGEN Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, QGEN has a market cap of 9.1B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while QGEN trades at $44.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas QGEN's P/E ratio is 18.25. In terms of profitability, TMO's ROE is +0.13%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, TMO is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for TMO.Check QGEN's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
TMO vs BLLN Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, BLLN has a market cap of 5.7B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while BLLN trades at $123.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas BLLN's P/E ratio is 175.83. In terms of profitability, TMO's ROE is +0.13%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, TMO is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BLLN's competition here
RadNet, Inc. (NASDAQ: RDNT)
TMO vs RDNT Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while RDNT trades at $70.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas RDNT's P/E ratio is 153.89. In terms of profitability, TMO's ROE is +0.13%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, TMO is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for TMO.Check RDNT's competition here
GRAIL Inc. (NASDAQ: GRAL)
TMO vs GRAL Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, GRAL has a market cap of 5.4B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while GRAL trades at $126.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas GRAL's P/E ratio is -12.83. In terms of profitability, TMO's ROE is +0.13%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, TMO is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check GRAL's competition here
Sotera Health Company (NASDAQ: SHC)
TMO vs SHC Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while SHC trades at $18.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas SHC's P/E ratio is 19.10. In terms of profitability, TMO's ROE is +0.13%, compared to SHC's ROE of +0.27%. Regarding short-term risk, TMO is similarly volatile compared to SHC. This indicates similar risk in terms of short-term price fluctuations for TMO.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
TMO vs SYNH Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas SYNH's P/E ratio is 61.40. In terms of profitability, TMO's ROE is +0.13%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, TMO is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for TMO.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
TMO vs VCYT Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while VCYT trades at $45.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas VCYT's P/E ratio is 22.72. In terms of profitability, TMO's ROE is +0.13%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, TMO is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for TMO.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
TMO vs CDNA Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while CDNA trades at $63.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas CDNA's P/E ratio is 75.81. In terms of profitability, TMO's ROE is +0.13%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, TMO is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
TMO vs OLK Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas OLK's P/E ratio is -96.59. In terms of profitability, TMO's ROE is +0.13%, compared to OLK's ROE of -0.07%. Regarding short-term risk, TMO is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for TMO.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
TMO vs WGS Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, WGS has a market cap of 2.6B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while WGS trades at $88.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas WGS's P/E ratio is 245.56. In terms of profitability, TMO's ROE is +0.13%, compared to WGS's ROE of -0.39%. Regarding short-term risk, TMO is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for TMO.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
TMO vs PSNL Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, PSNL has a market cap of 1.8B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while PSNL trades at $16.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas PSNL's P/E ratio is -15.10. In terms of profitability, TMO's ROE is +0.13%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, TMO is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
TMO vs OPK Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while OPK trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas OPK's P/E ratio is -6.07. In terms of profitability, TMO's ROE is +0.13%, compared to OPK's ROE of -0.06%. Regarding short-term risk, TMO is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for TMO.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
TMO vs CSTL Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while CSTL trades at $35.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas CSTL's P/E ratio is -54.26. In terms of profitability, TMO's ROE is +0.13%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, TMO is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
TMO vs FLGT Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, FLGT has a market cap of 630.5M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while FLGT trades at $22.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas FLGT's P/E ratio is 2220.00. In terms of profitability, TMO's ROE is +0.13%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, TMO is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for TMO.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
TMO vs GRALV Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas GRALV's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to GRALV's ROE of N/A. Regarding short-term risk, TMO is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for TMO.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
TMO vs NEO Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, NEO has a market cap of 496.7M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while NEO trades at $19.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas NEO's P/E ratio is 148.69. In terms of profitability, TMO's ROE is +0.13%, compared to NEO's ROE of -0.06%. Regarding short-term risk, TMO is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
TMO vs CO Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas CO's P/E ratio is 5.06. In terms of profitability, TMO's ROE is +0.13%, compared to CO's ROE of +0.11%. Regarding short-term risk, TMO is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
TMO vs MYGN Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, MYGN has a market cap of 393.8M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while MYGN trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas MYGN's P/E ratio is -32.08. In terms of profitability, TMO's ROE is +0.13%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, TMO is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
TMO vs FLDM Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas FLDM's P/E ratio is -4.74. In terms of profitability, TMO's ROE is +0.13%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, TMO is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for TMO.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
TMO vs BDSX Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, BDSX has a market cap of 236.9M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while BDSX trades at $29.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas BDSX's P/E ratio is -9.18. In terms of profitability, TMO's ROE is +0.13%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, TMO is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
TMO vs XGN Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, XGN has a market cap of 210.7M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while XGN trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas XGN's P/E ratio is -10.77. In terms of profitability, TMO's ROE is +0.13%, compared to XGN's ROE of -1.22%. Regarding short-term risk, TMO is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
TMO vs FRNM Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, FRNM has a market cap of 130.4M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while FRNM trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas FRNM's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to FRNM's ROE of N/A. Regarding short-term risk, TMO is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for TMO.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
TMO vs GTH Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas GTH's P/E ratio is -1.11. In terms of profitability, TMO's ROE is +0.13%, compared to GTH's ROE of -1.01%. Regarding short-term risk, TMO is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for TMO.Check GTH's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
TMO vs IMDX Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, IMDX has a market cap of 126.6M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while IMDX trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas IMDX's P/E ratio is -2.63. In terms of profitability, TMO's ROE is +0.13%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, TMO is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for TMO.Check IMDX's competition here
Genetic Technologies Limited (NASDAQ: GENE)
TMO vs GENE Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas GENE's P/E ratio is -38.25. In terms of profitability, TMO's ROE is +0.13%, compared to GENE's ROE of -1.85%. Regarding short-term risk, TMO is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for TMO.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
TMO vs SERA Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, SERA has a market cap of 77.9M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while SERA trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas SERA's P/E ratio is -3.14. In terms of profitability, TMO's ROE is +0.13%, compared to SERA's ROE of -0.47%. Regarding short-term risk, TMO is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
TMO vs PRPO Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, PRPO has a market cap of 42.2M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while PRPO trades at $23.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas PRPO's P/E ratio is -36.38. In terms of profitability, TMO's ROE is +0.13%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, TMO is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for TMO.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
TMO vs QUCY Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, QUCY has a market cap of 31.4M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while QUCY trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas QUCY's P/E ratio is -0.06. In terms of profitability, TMO's ROE is +0.13%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, TMO is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for TMO.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
TMO vs MDXH Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, MDXH has a market cap of 29M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while MDXH trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas MDXH's P/E ratio is -0.77. In terms of profitability, TMO's ROE is +0.13%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, TMO is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
TMO vs AKU Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas AKU's P/E ratio is -0.13. In terms of profitability, TMO's ROE is +0.13%, compared to AKU's ROE of -5.32%. Regarding short-term risk, TMO is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for TMO.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
TMO vs BNR Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, BNR has a market cap of 19.7M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while BNR trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas BNR's P/E ratio is -21.38. In terms of profitability, TMO's ROE is +0.13%, compared to BNR's ROE of -0.13%. Regarding short-term risk, TMO is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
TMO vs CEMI Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas CEMI's P/E ratio is -0.63. In terms of profitability, TMO's ROE is +0.13%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, TMO is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for TMO.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
TMO vs ENZ Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas ENZ's P/E ratio is -2.24. In terms of profitability, TMO's ROE is +0.13%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, TMO is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
TMO vs PMD Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas PMD's P/E ratio is -5.24. In terms of profitability, TMO's ROE is +0.13%, compared to PMD's ROE of -0.32%. Regarding short-term risk, TMO is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for TMO.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
TMO vs ME Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas ME's P/E ratio is -0.03. In terms of profitability, TMO's ROE is +0.13%, compared to ME's ROE of -42.03%. Regarding short-term risk, TMO is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for TMO.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
TMO vs MYNZ Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, TMO's ROE is +0.13%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, TMO is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MYNZ's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
TMO vs CHEK Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas CHEK's P/E ratio is -0.43. In terms of profitability, TMO's ROE is +0.13%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, TMO is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CHEK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
TMO vs BIAFW Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, BIAFW has a market cap of 9.6M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while BIAFW trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas BIAFW's P/E ratio is 1.02. In terms of profitability, TMO's ROE is +0.13%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, TMO is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BIAFW's competition here
Centogene N.V. (NASDAQ: CNTG)
TMO vs CNTG Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas CNTG's P/E ratio is -0.23. In terms of profitability, TMO's ROE is +0.13%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, TMO is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for TMO.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
TMO vs ADVB Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, ADVB has a market cap of 8.8M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while ADVB trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas ADVB's P/E ratio is -58.00. In terms of profitability, TMO's ROE is +0.13%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, TMO is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
TMO vs NDRA Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while NDRA trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas NDRA's P/E ratio is -0.90. In terms of profitability, TMO's ROE is +0.13%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, TMO is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
TMO vs APDN Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas APDN's P/E ratio is -0.10. In terms of profitability, TMO's ROE is +0.13%, compared to APDN's ROE of -7.23%. Regarding short-term risk, TMO is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
TMO vs NVTA Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas NVTA's P/E ratio is -0.00. In terms of profitability, TMO's ROE is +0.13%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, TMO is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
TMO vs LMDX Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas LMDX's P/E ratio is -0.01. In terms of profitability, TMO's ROE is +0.13%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, TMO is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for TMO.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
TMO vs LMDXW Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, TMO's ROE is +0.13%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, TMO is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check LMDXW's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
TMO vs BIAF Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, BIAF has a market cap of 3.3M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while BIAF trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas BIAF's P/E ratio is -0.93. In terms of profitability, TMO's ROE is +0.13%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, TMO is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BIAF's competition here
DermTech, Inc. (NASDAQ: DMTK)
TMO vs DMTK Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas DMTK's P/E ratio is -0.04. In terms of profitability, TMO's ROE is +0.13%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, TMO is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for TMO.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
TMO vs NOTV Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas NOTV's P/E ratio is -0.03. In terms of profitability, TMO's ROE is +0.13%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, TMO is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
TMO vs SQL Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas SQL's P/E ratio is -0.40. In terms of profitability, TMO's ROE is +0.13%, compared to SQL's ROE of -30.46%. Regarding short-term risk, TMO is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
TMO vs AWH Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas AWH's P/E ratio is -0.09. In terms of profitability, TMO's ROE is +0.13%, compared to AWH's ROE of +1.62%. Regarding short-term risk, TMO is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for TMO.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
TMO vs HTGM Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas HTGM's P/E ratio is -0.03. In terms of profitability, TMO's ROE is +0.13%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, TMO is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for TMO.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
TMO vs BIOC Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas BIOC's P/E ratio is -0.01. In terms of profitability, TMO's ROE is +0.13%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, TMO is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
TMO vs SQLLW Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, TMO's ROE is +0.13%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, TMO is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check SQLLW's competition here
iSpecimen Inc. (NASDAQ: ISPC)
TMO vs ISPC Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, ISPC has a market cap of 175K. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while ISPC trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas ISPC's P/E ratio is -0.04. In terms of profitability, TMO's ROE is +0.13%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, TMO is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ISPC's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
TMO vs WGSWW Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, TMO's ROE is +0.13%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, TMO is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for TMO.Check WGSWW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
TMO vs PRXL Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas PRXL's P/E ratio is 42.97. In terms of profitability, TMO's ROE is +0.13%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, TMO is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for TMO.Check PRXL's competition here
Danaher Corporation (NYSE: DHR-PA)
TMO vs DHR-PA Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, TMO's ROE is +0.13%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, TMO is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check DHR-PA's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
TMO vs OCDX Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas OCDX's P/E ratio is -42.28. In terms of profitability, TMO's ROE is +0.13%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, TMO is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for TMO.Check OCDX's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
TMO vs NDRAW Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas NDRAW's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, TMO is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NDRAW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
TMO vs MEUSW Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas MEUSW's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, TMO is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MEUSW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
TMO vs BNGOW Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas BNGOW's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, TMO is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
TMO vs CHEKZ Comparison September 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 249.1B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, TMO is priced at $675.00 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 29.09, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, TMO is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CHEKZ's competition here